SANUWAVE Health (SNWV) 10-Q 14 Aug 19 2019 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2019	Aug. 09, 2019
Document And Entity Information
Entity Registrant Name	SANUWAVE Health, Inc.
Entity Central Index Key	0001417663
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Current Reporting Status	Yes
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		187,484,224
Document Type	10-Q
Document Period End Date	Jun. 30, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q2
Amendment Flag	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Jun. 30, 2019	Dec. 31, 2018
CURRENT ASSETS
Cash and cash equivalents	$ 154,446	$ 364,549
Accounts receivable, net of allowance for doubtful accounts of $58,293 in 2019 and $33,045 in 2018	175,041	234,774
Due from related parties	0	1,228
Inventory	423,932	357,820
Prepaid expenses and other current assets	251,616	125,111
TOTAL CURRENT ASSETS	1,005,035	1,083,482
PROPERTY AND EQUIPMENT, net	85,782	77,755
RIGHT OF USE ASSETS	398,698	0
OTHER ASSETS	23,561	16,491
TOTAL ASSETS	1,513,076	1,177,728
CURRENT LIABILITIES
Accounts payable	1,456,727	1,592,643
Accrued expenses	795,458	689,280
Accrued employee compensation	865,900	340,413
Contract liabilities	114,814	131,797
Lease liability - right of use	167,437	0
Advances from related parties	585,022	0
Line of credit, related parties	726,009	883,224
Accrued interest, related parties	1,504,453	1,171,782
Short term note payable	3,079,767	1,883,163
Convertible promissory notes, net	2,860,478	2,652,377
Notes payable, related parties, net	5,372,743	5,372,743
Warrant liability	0	1,769,669
TOTAL CURRENT LIABILITIES	17,528,808	16,487,091
NON-CURRENT LIABILITIES
Contract liabilities	67,361	46,736
Lease liability - right of use	272,413	0
TOTAL NON-CURRENT LIABILITIES	339,774	46,736
TOTAL LIABILITIES	17,868,582	16,533,827
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS' DEFICIT
Preferred stock	0	0
COMMON STOCK, par value $0.001, 350,000,000 shares authorized; 188,650,891 and 155,665,138 issued and outstanding in 2019 and 2018, respectively	188,651	155,665
ADDITIONAL PAID-IN CAPITAL	103,774,485	101,153,882
ACCUMULATED DEFICIT	(120,254,865)	(116,602,778)
ACCUMULATED OTHER COMPREHENSIVE LOSS	(63,777)	(62,868)
TOTAL STOCKHOLDERS' DEFICIT	(16,355,506)	(15,356,099)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	1,513,076	1,177,728
Series A Convertible Preferred Stock
STOCKHOLDERS' DEFICIT
Preferred stock	0	0
Series B Convertible Preferred Stock
STOCKHOLDERS' DEFICIT
Preferred stock	$ 0	$ 0

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)	Jun. 30, 2019	Dec. 31, 2018
Accounts receivable, allowance for doubtful accounts	$ 58,293	$ 33,045
Preferred stock, par value	$ .001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ .001	$ 0.001
Common stock, shares authorized	350,000,000	350,000,000
Common stock, shares issued	188,650,891	155,665,138
Common stock, shares outstanding	188,650,891	155,665,138
Series A Convertible Preferred Stock
Preferred stock, par value	$ .001	$ 0.001
Preferred stock, shares authorized	6,175	6,175
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Series B Convertible Preferred Stock
Preferred stock, par value	$ .001	$ 0.001
Preferred stock, shares authorized	293	293
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0

Condensed Consolidated Statemen

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
REVENUES	$ 316,976	$ 453,210	$ 494,939	$ 797,482
COST OF REVENUES (exclusive of depreciation shown below)	185,881	166,643	279,734	332,109
GROSS MARGIN	131,095	286,567	215,205	465,373
OPERATING EXPENSES
Research and development	307,273	328,753	567,922	678,197
Selling and marketing	407,477	158,695	565,559	210,654
General and administrative	1,426,405	1,911,688	2,943,860	2,805,335
Depreciation	9,455	6,008	17,812	11,024
Loss on sale of property and equipment	0	3,170	0	3,170
TOTAL OPERATING EXPENSES	2,150,610	2,408,314	4,095,153	3,708,380
OPERATING LOSS	(2,019,515)	(2,121,747)	(3,879,948)	(3,243,007)
OTHER INCOME (EXPENSE)
Gain (loss) on warrant valuation adjustment	195,310	1,161,520	227,669	(1,812,162)
Interest expense, net	(160,215)	(1,735,509)	(308,476)	(3,291,265)
Interest expense, related party	(112,984)	(194,246)	(332,671)	(383,457)
Financing charge	(629,963)	0	(629,963)	0
Gain (loss) on foreign currency exchange	(7,064)	1,723	(8,359)	(15,023)
TOTAL OTHER INCOME (EXPENSE), NET	(714,916)	(766,512)	(1,051,800)	(5,501,907)
NET LOSS	(2,734,431)	(2,888,259)	(4,931,748)	(8,744,914)
OTHER COMPREHENSIVE INCOME (LOSS)
Foreign currency translation adjustments	1,489	(11,904)	(909)	(10,969)
TOTAL COMPREHENSIVE LOSS	$ (2,732,942)	$ (2,900,163)	$ (4,932,657)	$ (8,755,883)
LOSS PER SHARE:
Net loss - basic and diluted	$ (0.02)	$ (0.02)	$ (0.03)	$ (0.06)
Weighted average shares outstanding - basic and diluted	174,730,747	148,582,386	165,921,811	144,168,215
Product
REVENUES	$ 220,667	$ 243,465	$ 285,232	$ 482,033
COST OF REVENUES (exclusive of depreciation shown below)	178,458	128,716	243,570	254,309
License fees
REVENUES	66,808	203,757	173,058	287,873
Other
REVENUES	29,501	5,988	36,649	27,576
COST OF REVENUES (exclusive of depreciation shown below)	$ 7,423	$ 37,927	$ 36,164	$ 77,800

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Deficit - USD ($)	Preferred Stock	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Accumulated Other Comprehensive Loss	Total
Balances (in shares) at Dec. 31, 2017	0	139,300,122
Balances at Dec. 31, 2017	$ 0	$ 139,300	$ 94,995,040	$ (104,971,384)	$ (43,783)	$ (9,880,827)
Net loss				(5,856,655)		(5,856,655)
Cashless warrant exercises (in shares)		1,023,130
Cashless warrant exercises		$ 1,023	117,815			118,838
Proceeds from warrant exercise (in shares)		175,666
Proceeds from warrant exercise		$ 176	13,352			13,528
Shares issued for services (in shares)		551,632
Shares issued for services		$ 552	78,448			79,000
Warrants issued with convertible promissory note			808,458			808,458
Beneficial conversion feature on convertible promissory notes			709,827			709,827
Warrants issued with promissory note			36,104			36,104
Beneficial conversion feature on promissory notes			35,396			35,396
Foreign currency translation adjustment					935	935
Balances (in shares) at Mar. 31, 2018	0	141,050,550
Balances at Mar. 31, 2018	$ 0	$ 141,051	96,794,440	(110,828,039)	(42,848)	(13,935,396)
Balances (in shares) at Dec. 31, 2017	0	139,300,122
Balances at Dec. 31, 2017	$ 0	$ 139,300	94,995,040	(104,971,384)	(43,783)	(9,880,827)
Net loss						(8,744,914)
Proceeds from warrant exercise						38,528
Shares issued for services						106,500
Stock-based compensation						836,796
Balances (in shares) at Jun. 30, 2018	0	151,852,757
Balances at Jun. 30, 2018	$ 0	$ 151,853	99,059,031	(113,716,298)	(54,752)	(14,560,166)
Balances (in shares) at Mar. 31, 2018	0	141,050,550
Balances at Mar. 31, 2018	$ 0	$ 141,051	96,794,440	(110,828,039)	(42,848)	(13,935,396)
Net loss				(2,888,259)		(2,888,259)
Cashless warrant exercises (in shares)		4,606,675
Cashless warrant exercises		$ 4,607	(4,607)			0
Proceeds from warrant exercise (in shares)		227,273
Proceeds from warrant exercise		$ 227	24,773			25,000
Shares issued for services (in shares)		71,532
Shares issued for services		$ 71	27,429			27,500
Conversion of promissory notes (in shares)		5,896,727
Conversion of promissory notes		$ 5,897	642,743			648,640
Warrants issued for services			737,457			737,457
Stock-based compensation			836,796			836,796
Foreign currency translation adjustment					(11,904)	(11,904)
Balances (in shares) at Jun. 30, 2018	0	151,852,757
Balances at Jun. 30, 2018	$ 0	$ 151,853	99,059,031	(113,716,298)	(54,752)	(14,560,166)
Balances (in shares) at Dec. 31, 2018	0	155,665,138
Balances at Dec. 31, 2018	$ 0	$ 155,665	101,153,882	(116,602,778)	(62,868)	(15,356,099)
Net loss				(2,197,317)		(2,197,317)
Cashless warrant exercises (in shares)		704,108
Cashless warrant exercises		$ 704	(704)			0
Proceeds from warrant exercise (in shares)		620,000
Proceeds from warrant exercise		$ 620	52,580			53,200
Conversion of short term notes payable to equity (in shares)		3,333,334
Conversion of short term notes payable to equity		$ 3,334	263,333			266,667
Reclassification of warrant liability to equity			262,339	1,279,661		1,542,000
Foreign currency translation adjustment					(2,398)	(2,398)
Balances (in shares) at Mar. 31, 2019	0	160,322,580
Balances at Mar. 31, 2019	$ 0	$ 160,323	101,731,430	(117,520,434)	(65,266)	(15,693,947)
Balances (in shares) at Dec. 31, 2018	0	155,665,138
Balances at Dec. 31, 2018	$ 0	$ 155,665	101,153,882	(116,602,778)	(62,868)	(15,356,099)
Net loss						(4,931,748)
Proceeds from warrant exercise						1,403,257
Shares issued for services						0
Stock-based compensation						31,758
Balances (in shares) at Jun. 30, 2019	0	188,650,891
Balances at Jun. 30, 2019	$ 0	$ 188,651	103,774,485	(120,254,865)	(63,777)	(16,355,506)
Balances (in shares) at Mar. 31, 2019	0	160,322,580
Balances at Mar. 31, 2019	$ 0	$ 160,323	101,731,430	(117,520,434)	(65,266)	(15,693,947)
Net loss				(2,734,431)		(2,734,431)
Cashless warrant exercises (in shares)		2,997,375
Cashless warrant exercises		$ 2,997	13,003			16,000
Proceeds from warrant exercise (in shares)		17,051,769
Proceeds from warrant exercise		$ 17,052	1,333,005			1,350,057
Conversion of short term notes payable to equity (in shares)		8,279,167
Conversion of short term notes payable to equity		$ 8,279	629,222			637,501
Warrants issued for services			36,067			36,067
Stock-based compensation			31,758			31,758
Foreign currency translation adjustment					1,489	1,489
Balances (in shares) at Jun. 30, 2019	0	188,650,891
Balances at Jun. 30, 2019	$ 0	$ 188,651	$ 103,774,485	$ (120,254,865)	$ (63,777)	$ (16,355,506)

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (4,931,748)	$ (8,744,914)
Adjustments to reconcile loss from continuing operations to net cash used by operating activities
Depreciation	17,812	11,024
Change in allowance for doubtful accounts	25,248	(61,344)
Stock-based compensation - employee, directors and advisors	31,758	836,796
Loss (gain) on warrant valuation adjustment	(227,669)	1,812,162
Amortization of operating lease	(3,471)	0
Amortization of debt issuance costs	0	2,683,936
Amortization of debt discount	0	75,484
Stock issued for consulting services	0	106,500
Warrants issued for consulting services	36,067	737,457
Loss on sale of fixed assets	0	3,170
Accrued interest	306,695	168,787
Interest payable, related parties	332,671	156,746
Changes in operating assets and liabilities
Accounts receivable - trade	34,485	69,534
Inventory	(66,112)	15,216
Prepaid expenses	(126,505)	(54,528)
Contract assets	0	(40,000)
Due from related parties	1,228	0
Other assets	(7,070)	(3,872)
Accounts payable	(135,916)	(425,489)
Accrued expenses	106,178	91,459
Accrued employee compensation	525,487	194,194
Accrued financing charge	629,963	0
Operating leases	44,623	0
Contract liabilties	3,642	769,480
NET CASH USED BY OPERATING ACTIVITIES	(3,402,634)	(1,598,202)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchases of property and equipment	(25,839)	(13,612)
NET CASH USED BY INVESTING ACTIVITIES	(25,839)	(13,612)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from short term note	1,215,000	85,000
Proceeds from warrant exercise	1,403,257	38,528
Advances from related parties	585,022	156,000
Waived proceeds from warrant exercise	16,000	0
Proceeds from convertible promissory notes, net	0	1,159,785
Proceeds from line of credit, related party	0	280,500
Proceeds from note payable, product	0	96,708
Payment on line of credit, related party	0	(144,500)
Payments on note payable, product	0	(96,708)
Payments on advances from related parties	0	(12,000)
NET CASH PROVIDED BY FINANCING ACTIVITIES	3,219,279	1,563,313
EFFECT OF EXCHANGE RATES ON CASH	(909)	(10,969)
NET DECREASE IN CASH AND CASH EQUIVALENTS	(210,103)	(59,470)
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD	364,549	730,184
CASH AND CASH EQUIVALENTS, END OF PERIOD	154,446	670,714
NONCASH INVESTING ACTIVITIES
Conversion of short term notes payable	724,168	0
Conversion of line of credit, related party to equity	180,000	0
Reclassification of warrant liability to equity	262,339	0
Advances from related and unrelated parties converted to Convertible promissory note	0	310,000
Accounts payable converted to Convertible promissory notes	0	120,000
Beneficial conversion feature on convertible debt	0	745,223
Warrants issued for debt	$ 0	$ 844,562

Note 1 - Nature of the Business

Note 1 - Nature of the Business	6 Months Ended
	Jun. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of the Business	SANUWAVE Health, Inc. and subsidiaries (the “Company”) is a shock wave technology company using a patented system of noninvasive, high-energy, acoustic shock waves for regenerative medicine and other applications. The Company’s initial focus is regenerative medicine – utilizing noninvasive, acoustic shock waves to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, musculoskeletal and vascular structures. The Company’s lead regenerative product in the United States is the dermaPACE® device, used for treating diabetic foot ulcers, which was subject to two double-blinded, randomized Phase III clinical studies. On December 28, 2017, the U.S. Food and Drug Administration (the “FDA”) notified the Company to permit the marketing of the dermaPACE System for the treatment of diabetic foot ulcers in the United States. The Company’s portfolio of healthcare products and product candidates activate biologic signaling and angiogenic responses, including new vascularization and microcirculatory improvement, helping to restore the body’s normal healing processes and regeneration. The Company intends to apply its Pulsed Acoustic Cellular Expression (PACE®) technology in wound healing, orthopedic, plastic/cosmetic and cardiac conditions. In 2019, the Company has been marketing the dermaPACE System for placement in the United States and the European Conformity Marking (CE Mark) devices and accessories in Europe, Canada, Asia and Asia/Pacific. The Company generates revenues streams from product sales, licensing transactions and other activities. Basis of Presentation The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with United States generally accepted accounting principles (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 8-03 of Regulation S-X. Accordingly, these condensed consolidated financial statements do not include all the information and footnotes required by U.S. GAAP for complete financial statements. The financial information as of June 30, 2019 and for the three and six months ended June 30, 2019 and 2018 is unaudited; however, in the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three and six months ended June 30, 2019 are not necessarily indicative of the results that may be expected for any other interim period or for the year ending December 31, 2019. The condensed consolidated balance sheet at December 31, 2018 has been derived from the audited consolidated financial statements at that date but does not include all of the information and footnotes required by GAAP for complete financial statements. These financial statements should be read in conjunction with the Company’s Form 10-K filed with the Securities and Exchange Commission on April 1, 2019 (the “2018 Annual Report”).

Note 2 - Going Concern

Note 2 - Going Concern	6 Months Ended
	Jun. 30, 2019
Note 2 - Going Concern
Going Concern	The Company does not currently generate significant recurring revenue and will require additional capital during 2019. As of June 30, 2019, the Company had an accumulated deficit of $120,254,865 and cash and cash equivalents of $154,446. For the six months ended June 30, 2019 and 2018, the net cash used by operating activities was $3,402,634 and $1,598,202, respectively. The Company incurred a net loss of $4,931,748 for the six months ended June 30, 2019 and a net loss of $8,744,914 for the six months ended June 30, 2018. The operating losses and the events of default on the Company’s short term notes payable (see Note 7), the Company’s convertible promissory notes and the notes payable, related parties (see Note 8) indicate substantial doubt about the Company’s ability to continue as a going concern for a period of at least twelve months from the filing of this report. The continuation of the Company’s business is dependent upon raising additional capital during the remainder of 2019 to fund operations. Management’s plans are to obtain additional capital through investments by strategic partners for market opportunities, which may include strategic partnerships or licensing arrangements, or raise capital through the conversion of outstanding warrants, the issuance of common or preferred stock, securities convertible into common stock, or secured or unsecured debt. These possibilities, to the extent available, may be on terms that result in significant dilution to the Company’s existing shareholders. Although no assurances can be given, management of the Company believes that potential additional issuances of equity or other potential financing transactions as discussed above should provide the necessary funding for the Company to continue as a going concern. If these efforts are unsuccessful, the Company may be forced to seek relief through a filing under the U.S. Bankruptcy Code. The condensed consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

Note 3 - Summary of Significant

Note 3 - Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2019
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	The significant accounting policies followed by the Company are summarized below and should be read in conjunction with the 2018 Annual Report: Principles of consolidation Estimates Reclassifications – Inventory Recently Issued or Adopted Accounting Standards In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-02, Leases (Topic 842). In May 2017, the FASB issued ASU No. 2017-09, Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting In July 2017, the FASB issued ASU No. 2017-11, Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480): Derivatives and Hedging (Topic 815): (Part I) Accounting for Certain Financial Instruments with Down Round Features, (Part II) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception. In June 2018, the FASB issued ASU 2018-07, Compensation – Stock Compensation (Topic 718) – Improvements to Nonemployee Share-Based Payment Accounting In July 2018, the FASB issued ASU No. 2018-09, Codification Improvements In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement

Note 4 - Accrued Expenses

Note 4 - Accrued Expenses	6 Months Ended
	Jun. 30, 2019
Payables and Accruals [Abstract]
Accrued Expenses	Accrued expenses consist of the following: June 30, December 31, 2019 2018 Accrued board of directors' fees $ 300,000 $ 200,000 Accrued executive severance 145,000 136,000 Accrued outside services 124,078 115,118 Accrued inventory 116,502 Accrued travel 60,000 58,993 Accrued legal fees 35,000 - Accrued clinical study expenses 13,650 13,650 Accrued related party advances - 101,137 Deferred rent - 44,623 Accrued computer equipment - 8,752 Accrued other 1,228 11,007 $ 795,458 $ 689,280

Note 5 - Contract Liabilities

Note 5 - Contract Liabilities	6 Months Ended
	Jun. 30, 2019
Contract with Customer, Liability [Abstract]
Contract liabilities	As of June 30, 2019, the Company has contract assets and liabilities from contracts with customers (see Note 12). Contract liabilities consist of the following: June 30, December 31, 2019 2018 Deposit on product $ 62,946 $ 92,950 Service agreement 115,538 57,365 Other 3,691 28,218 Total Contract liabilities 182,175 178,533 Non-Current (67,361 ) (46,736 ) Total Current $ 114,814 $ 131,797 The timing of the Company’s revenue recognition may differ from the timing of payment by its customers. A receivable is recorded when revenue is recognized prior to payment and the Company has an unconditional right to payment. Alternatively, when payment precedes the satisfaction of performance obligations, the Company records a contract liability (deferred revenue) until the performance obligations are satisfied. Of the aggregate $182,175 of contract liability balances as of June 30, 2019, the Company expects to satisfy its remaining performance obligations associated with $114,814 and $67,361 of contract liability balances within the next twelve months and following forty-eight months, respectively. Of the aggregate $178,533 of contract liability balances as of December 31, 2018, the Company expects to satisfy its remaining performance obligations associated with $131,797 and $46,736 of contract liability balances within the next twelve months and following forty-eight months, respectively.

Note 6 - Advances From Related

Note 6 - Advances From Related Parties	6 Months Ended
	Jun. 30, 2019
Related Party Transactions [Abstract]
Advances From Related Parties	During the six months ended June 30, 2019, the Company has received $585,022 for warrant exercises. Due to the timing of receipt of cash and issuance of the Company’s common stock the funds have been recorded as advances from related parties and will be properly recorded as equity when the common stock is issued.

Note 7 - Short Term Notes Payab

Note 7 - Short Term Notes Payable	6 Months Ended
	Jun. 30, 2019
Notes Payable [Abstract]
Short Term Notes Payable	During the six months ended June 30, 2019, the Company entered into short term notes payable in the total principal amount of $1,215,000 with an interest rate of 5% per annum. The total principal, accrued interest and accrued financing costs of short term notes payable was $3,079,767 as of June 30, 2019 and are due and payable six months from the date of issuance of the respective notes. On December 26, 2018, the Company defaulted on the short term notes payable issued on June 26, 2018 and began accruing interest at the default interest rate of 10%. On January 2, 2019, the Company defaulted on the short term notes payable issued on July 2, 2018 and began accruing interest at the default interest rate of 10%. On January 30, 2019, the Company defaulted on the short term notes payable issued on July 30, 2018 and began accruing interest at the default interest rate of 10%. In May 2019, the Company defaulted on the short term notes payable issued during November 2018 and began accruing interest at the default rate of 10%. On June 30, 2019, the Company defaulted on the short term notes payable issued on December 31, 2018 and will begin accruing interest at the default interest rate of 10% in July 2019.

Note 8 - Notes Payable, Related

Note 8 - Notes Payable, Related Parties	6 Months Ended
	Jun. 30, 2019
Notes Payable [Abstract]
Notes Payable, Related Parties	The notes payable, related parties as amended were issued in conjunction with the Company’s purchase of the orthopedic division of HealthTronics, Inc. The notes payable, related parties bear interest at 8% per annum, as amended. All remaining unpaid accrued interest and principal was due on December 31, 2018, as amended. HealthTronics, Inc. is a related party because they are a shareholder in the Company and have a security agreement with the Company detailed below. The Company is a party to a security agreement with HealthTronics, Inc. to provide a first security interest in the assets of the Company. During any period when an Event of Default occurs, the applicable interest rate shall increase by 2% per annum. Events of Default under the notes payable, related parties have occurred and are continuing on account of the failure of SANUWAVE, Inc., a Delaware corporation, a wholly owned subsidiary of the Company and the borrower under the notes payable, related parties, to make the required payments of interest which were due on December 31, 2016, March 31, 2017, June 30, 2017, September 30, 2017, December 31, 2017, June 30, 2018, September 30, 2018, December 31, 2018, March 31, 2019 and June 30, 2019 (collectively, the “Defaults”). As a result of the Defaults, the notes payable, related parties have been accruing interest at the rate of 10% per annum since January 2, 2017 and continue to accrue interest at such rate. The Company will be required to make mandatory prepayments of principal on the notes payable, related parties equal to 20% of the proceeds received by the Company through the issuance or sale of any equity securities in cash or through the licensing of the Company’s patents or other intellectual property rights. The notes payable, related parties had an aggregate outstanding principal balance of $5,372,743 at June 30, 2019 and December 31, 2018. Accrued interest, related parties currently payable totaled $1,504,453 at June 30, 2019 and $1,171,782 at December 31, 2018. Interest expense on notes payable, related parties totaled $112,984 and $194,246 for the three months ended June 30, 2019 and 2018, respectively and $332,671 and $383,457 for the six months ended June 30, 2019 and 2018, respectively.

Note 9 - Equity Transactions

Note 9 - Equity Transactions	6 Months Ended
	Jun. 30, 2019
Equity [Abstract]
Equity Transactions	Warrant Exercise During the six months ended June 30, 2019, the Company issued 17,671,769 shares of Common Stock upon the exercise of 17,671,769 Class L Warrants, Class O Warrants and Series A Warrants to purchase shares of stock under the terms of the respective warrant agreements. Cashless Warrant Exercise During the six months ended June 30, 2019, the Company issued 3,501,483 shares of Common Stock upon the cashless exercise of 6,755,522 Class N Warrants, Class L Warrants and Series A Warrants to purchase shares of stock under the terms of the respective warrant agreements. During the six months ended June 30, 2019, the Company issued 200,000 shares of Common Stock on a cashless basis upon the exercise of 200,000 Class L Warrants to purchase shares of stock under the terms of the respective warrant agreements. The Common Stock was issued on a cashless basis as a result of email breach in March 2019. The warrant holder sent the funds to an incorrect bank account as a result of the email breach and the Company elected to waive the requirement to cash exercise and allowed the warrant holder to net exercise. Conversion of short term notes payable to equity During the six months ended June 30, 2019, the Company issued 11,612,501 shares of Common Stock upon the conversion of short term note payable in the principal amount of $904,168 with the receipt of notices of Class L and Series A warrant exercises for 11,375,001 Class L Warrants and Series A Warrants , all pursuant to the terms of the short term note payable.

Note 10 - Warrants

Note 10 - Warrants	6 Months Ended
	Jun. 30, 2019
Note 10 - Warrants
Warrants	A summary of the warrant activity during the six months ended June 30, 2019, is presented as follows: Outstanding Outstanding as of as of December 31, June 30, Warrant class 2018 Issued Exercised Expired 2019 Class K Warrants 7,200,000 - - - 7,200,000 Class L Warrants 57,258,339 - (57,258,339) - - Class N Warrants 30,451,815 - (6,237,499) - 24,214,316 Class O Warrants 7,929,091 - (140,000) - 7,789,091 Class P Warrants - 365,000 - - 365,000 Series A Warrants 1,155,682 - (1,155,682) - - 103,994,927 365,000 (64,791,520) - 39,568,407 A summary of the warrant exercise price per share and expiration date is presented as follows: Exercise Expiration price per share date Class K Warrants $ 0.08 June 2025 Class K Warrants $ 0.11 August 2027 Class N Warrants $ 0.11 September 2019 Class O Warrants $ 0.11 December 2019 Class P Warrants $ 0.20 June 2024 The Class L Warrants and Series A Warrants expired on May 1, 2019. The warrant holders indicated their intent to exercise prior to the expiration date but the shares have not been issued by the Company as of June 30, 2019. See Subsequent Events (note 16) for issuance of outstanding warrants. The exercise price of the Class K Warrants and the Series A Warrants are subject to a “down-round” anti-dilution adjustment if the Company issues or is deemed to have issued certain securities at a price lower than the then applicable exercise price of the warrants. Accordingly, the Company has classified such warrants as derivative liabilities. The Class K Warrants may be exercised on a physical settlement or on a cashless basis. The Series A Warrants may be exercised on a physical settlement basis if a registration statement underlying the warrants is effective. If a registration statement is not effective (or the prospectus contained therein is not available for use) for the resale by the holder of the Series A Warrants, then the holder may exercise the warrants on a cashless basis. On June 11, 2019, the Company issued Class P Warrant Agreements to vendors to purchase 265,000 shares of common stock at an exercise price of $0.20 per share. Each Class P Warrant represents the right to purchase one share of Common Stock. The estimated fair value of the Class P Warrants at the grant date was $36,067 and was recorded as selling and marketing expense and an increase to additional paid-in capital. The warrants vested upon issuance and expire on June 11, 2024. On June 24, 2019, the Company issued Class P Warrant Agreement to a vendor to purchase up to 100,000 shares of common stock at an exercise price of $0.20 per share. Each Class P Warrant represents the right to purchase one share of Common Stock. The estimated fair value of the Class P Warrant will be recorded as selling and marketing expense and an increase to additional paid-in capital as the warrants are earned per the milestones. The warrants vested upon issuance and expire on June 24, 2024. The Class K Warrants and the Series A Warrants are derivative financial instruments. The estimated fair value of the Class K Warrants at the date of grant was $36,989 and recorded as debt discount, which is accreted to interest expense through the maturity date of the related notes payable, related parties. The estimated fair values of the Series A Warrants and the Series B Warrants at the date of grant were $557,733 for the warrants issued in conjunction with the 2014 Private Placement and $47,974 for the warrants issued in conjunction with the 18% Convertible Promissory Notes. The fair value of the Series A Warrants and Series B Warrants were recorded as equity issuance costs in 2014, a reduction of additional paid-in capital. The Series B Warrants expired unexercised in March 2015. The estimated fair values were determined using a binomial option pricing model based on various assumptions. The Company’s derivative liabilities have been classified as Level 3 instruments and are adjusted to reflect estimated fair value at each period end, with any decrease or increase in the estimated fair value being recorded in other income or expense accordingly, as adjustments to the fair value of derivative liabilities. A summary of the changes in the warrant liability during the six months ended June 30, 2019, is presented as follows: Class K Series A Warrants Warrants Total Warrant liability as of December 31, 2018 $ 1,542,000 $ 227,669 $ 1,769,669 Change in fair value - (32,359 ) (32,359 ) Expired - (195,310 ) (195,310 ) Reclassification due to Adoption of ASU 2017-11 (see Note 3) (1,542,000 ) - (1,542,000 ) Warrant liability as of June 30, 2019 $ - $ - $ -

Note 11 - Commitments and Conti

Note 11 - Commitments and Contingencies	6 Months Ended
	Jun. 30, 2019
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Operating Leases The Company is a party to certain operating leases. In August 2016, the Company entered into a lease agreement for 7,500 square feet of office space for office, research and development, quality control, production and warehouse space which expires on December 31, 2021. On February 1, 2018, the Company entered into an amendment to the lease agreement for an additional 380 square feet of office space for storage which expires on December 31, 2021. On January 2, 2019, the Company entered into a second amendment to the lease agreement for an additional 2,297 square feet of office space for office space which expires on December 31, 2021. Under the terms of the lease, the Company pays monthly rent of $14,651, subject to a 3% adjustment on an annual basis. Right of use assets and Lease liability – right of use consist of the following: June 30, 2019 Right of use assets $ 398,698 June 30, 2019 Lease liability - right of use Current portion $ 167,437 Long term portion 272,413 $ 439,850 Cash paid for amounts included in the measurement of lease liabilities for the six months ended June 30, 2019 was $44,623 and was included in Net cash used in operating activities in it condensed consolidated statement of cash flows. Upon adoption of ASC 842 on January 1, 2019, the Company increased non-cash balances of right of use assets and lease liability – right of use by $476,029 and $520,652, respectively. As of June 30, 2019, the maturities of the Company’s lease liability – right of use consist of the following: Year ending December 31, Amount 2019 (remainder) $ 94,213 2020 191,713 2021 197,462 Total lease payments 483,388 Less: Present value adjustment (43,538 ) Lease liability - right of use $ 439,850 As required, the following disclosure is provided for periods prior to adoption. Minimum future lease payments that have initial or remaining lease terms in excess of one year consist of the following: Year ending December 31, Amount 2019 (remainder) $ 94,213 2020 191,713 2021 197,462 Total $ 483,388 Rent expense for the three months ended June 30, 2019 and 2018 was $54,698 and $36,138, respectively, and for the six months ended June 30, 2018 and 2017 was $107,536 and $72,020, respectively. As of June 30, 2019, the Company had no leases that were classified as a financing lease. As of June 30, 2019, the Company did not have additional operating or financing leases that have yet commenced. Litigation The Company is a defendant in various legal actions, claims and proceedings arising in the ordinary course of business, including claims related to breach of contracts and intellectual property matters resulting from our business activities. As with most actions such as these, an estimation of any possible and/or ultimate liability cannot always be determined. We believe that all pending claims, if adversely decided, would not have a material adverse effect on our business, financial position or results of operations.

Note 12 - Revenue

Note 12 - Revenue	6 Months Ended
	Jun. 30, 2019
Revenue from Contract with Customer [Abstract]
Revenue	Disaggregation of Revenue The disaggregation of revenue is based on geographical region. The following table presents revenue from contracts with customers for the three and six months ended June 30, 2019 and 2018: Three months ended March 31, 2019 Three months ended March 31, 2018 United States International Total United States International Total Product $ 120,488 $ 100,179 $ 220,667 $ 18,893 $ 224,572 $ 243,465 License fees 6,250 60,558 66,808 6,250 197,507 203,757 Other Revenue - 29,501 29,501 - 5,988 5,988 $ 126,738 $ 190,238 $ 316,976 $ 25,143 $ 428,067 $ 453,210 Six months ended June 30, 2019 Six months ended June 30, 2018 United States International Total United States International Total Product $ 138,167 $ 147,065 $ 285,232 $ 135,340 $ 346,693 $ 482,033 License fees 12,500 160,558 173,058 12,500 275,373 287,873 Other Revenue - 36,649 36,649 - 27,576 27,576 $ 150,667 $ 344,272 $ 494,939 $ 147,840 $ 649,642 $ 797,482 Management routinely assesses the financial strength of its customers and, as a consequence, believes accounts receivable are stated at the net realizable value and credit risk exposure is limited. Three distributors accounted for 30%, 28% and 15% of revenues for the six months ended June 30, 2019 and 63%, 0% and 58% of accounts receivable at June 30, 2019. Three distributors and partners accounted for 24%, 60% and 7% of accounts receivable at December 31, 2018.

Note 13 - Related Party Transa

Note 13 - Related Party Transactions	6 Months Ended
	Jun. 30, 2019
Related Party Transactions [Abstract]
Related Party Transactions	During the three and six months ended June 30, 2019 and 2018, the Company recorded $17,678 and $114,810 and $138,167 and $124,491, respectively, in revenue from an entity owned by A. Michael Stolarski, a member of the Company’s board of directors and an existing shareholder of the Company. Contract liabilities includes a balance at June 30, 2019 and 2018, of $102,899 and $53,682, respectively and the Accrued expenses balance includes a balance at June 30, 2019 and 2018, of $0 and $130,478, respectively from this related party.

Note 14 - Stock-based Compensat

Note 14 - Stock-based Compensation	6 Months Ended
	Jun. 30, 2019
Share-based Payment Arrangement, Noncash Expense [Abstract]
Stock-based Compensation	On June 14, 2019, the Company granted to an independent contractor an option to purchase up to 475,000 shares of the Company’s common stock at an exercise price of $0.18 per share. 100,000 shares subject to the option vested upon issuance and the remaining 375,000 shares subject to the option will vest based on performance milestones. Using a “closed-form” Black-Scholes option pricing model, management has determined that the vested shares had a fair value per share of $0.15 resulting in compensation expense of $15,000. The vested compensation cost was recognized upon grant. The unvested compensation cost will be recognized as the performance milestones are completed. On June 11, 2019, the Company granted to two new employees options to purchase 105,000 shares of the Company’s common stock at an exercise price of $0.16 per share and vested upon issuance. Using the Black-Scholes option pricing model, management has determined that the shares subject to the option had a fair value per share of $0.1596 resulting in compensation expense of $16,758. Compensation cost was recognized upon grant. The Company recognized as compensation cost for all outstanding stock options granted to employees, directors and advisors, $31,758 and $836,796 for the three months ended June 30, 2019 and 2018, respectively, and $31,758 and $836,796 for the six months ended June 30, 2019 and 2018, respectively. The range of exercise prices for options was $0.04 to $2.00 for options outstanding at June 30, 2019 and December 31, 2018, respectively. The aggregate intrinsic value for all vested and exercisable options was $664,516 and $2,085,866 at June 30, 2019 and December 31, 2018, respectively. The weighted average remaining contractual term for outstanding exercisable stock options was 6.92 and 7.4 years as of June 30, 2019 and December 31, 2018, respectively.

Note 15 - Earnings (Loss) Per S

Note 15 - Earnings (Loss) Per Share	6 Months Ended
	Jun. 30, 2019
LOSS PER SHARE:
Earnings (Loss) Per Share	Basic net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding for the period. Diluted net loss per share reflects the potential dilution that could occur if securities or other instruments to issue common stock were exercised or converted into common stock. Potentially dilutive securities are excluded from the computation of diluted net loss per share as their inclusive would be anti-dilutive and consist of the following: June 30, June 30, 2019 2018 Options 32,183,385 23,723,385 Warrants 39,568,407 108,355,714 Shares issuable 28,789,228 - Convertible promissory notes 26,004,347 - 126,545,367 132,079,099

Note 16 - Subsequent Events

Note 16 - Subsequent Events	6 Months Ended
	Jun. 30, 2019
Subsequent Events [Abstract]
Subsequent Events	The Company evaluates events that have occurred after the balance sheet date but before the financial statements are issued.

Note 3 - Summary of Significa_2

Note 3 - Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2019
Accounting Policies [Abstract]
Principles of consolidation	Principles of consolidation
Estimates	Estimates
Reclassifications	Reclassifications –
Inventory	Inventory
Recently Issued Accounting Standards	Recently Issued or Adopted Accounting Standards In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-02, Leases (Topic 842). In May 2017, the FASB issued ASU No. 2017-09, Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting In July 2017, the FASB issued ASU No. 2017-11, Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480): Derivatives and Hedging (Topic 815): (Part I) Accounting for Certain Financial Instruments with Down Round Features, (Part II) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception. In June 2018, the FASB issued ASU 2018-07, Compensation – Stock Compensation (Topic 718) – Improvements to Nonemployee Share-Based Payment Accounting In July 2018, the FASB issued ASU No. 2018-09, Codification Improvements In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement

Note 4 - Accrued Expenses (Tabl

Note 4 - Accrued Expenses (Tables)	6 Months Ended
	Jun. 30, 2019
Payables and Accruals [Abstract]
Accrued expenses	June 30, December 31, 2019 2018 Accrued board of directors' fees $ 300,000 $ 200,000 Accrued executive severance 145,000 136,000 Accrued outside services 124,078 115,118 Accrued inventory 116,502 Accrued travel 60,000 58,993 Accrued legal fees 35,000 - Accrued clinical study expenses 13,650 13,650 Accrued related party advances - 101,137 Deferred rent - 44,623 Accrued computer equipment - 8,752 Accrued other 1,228 11,007 $ 795,458 $ 689,280

Note 5 - Contract Liabilities (

Note 5 - Contract Liabilities (Tables)	6 Months Ended
	Jun. 30, 2019
Contract with Customer, Liability [Abstract]
Contract liabilities	June 30, December 31, 2019 2018 Deposit on product $ 62,946 $ 92,950 Service agreement 115,538 57,365 Other 3,691 28,218 Total Contract liabilities 182,175 178,533 Non-Current (67,361 ) (46,736 ) Total Current $ 114,814 $ 131,797

Note 10 - Warrants (Tables)

Note 10 - Warrants (Tables)	6 Months Ended
	Jun. 30, 2019
Note 10 - Warrants
Warrant activity	Outstanding Outstanding as of as of December 31, June 30, Warrant class 2018 Issued Exercised Expired 2019 Class K Warrants 7,200,000 - - - 7,200,000 Class L Warrants 57,258,339 - (57,258,339) - - Class N Warrants 30,451,815 - (6,237,499) - 24,214,316 Class O Warrants 7,929,091 - (140,000) - 7,789,091 Class P Warrants - 365,000 - - 365,000 Series A Warrants 1,155,682 - (1,155,682) - - 103,994,927 365,000 (64,791,520) - 39,568,407
Warrant exercise price per share	Exercise Expiration price per share date Class K Warrants $ 0.08 June 2025 Class K Warrants $ 0.11 August 2027 Class N Warrants $ 0.11 September 2019 Class O Warrants $ 0.11 December 2019 Class P Warrants $ 0.20 June 2024
Changes in warrant liability	Class K Series A Warrants Warrants Total Warrant liability as of December 31, 2018 $ 1,542,000 $ 227,669 $ 1,769,669 Change in fair value - (32,359 ) (32,359 ) Expired - (195,310 ) (195,310 ) Reclassification due to Adoption of ASU 2017-11 (see Note 3) (1,542,000 ) - (1,542,000 ) Warrant liability as of June 30, 2019 $ - $ - $ -

Note 11 - Commitments and Con_2

Note 11 - Commitments and Contingencies (Tables)	6 Months Ended
	Jun. 30, 2019
Commitments and Contingencies Disclosure [Abstract]
Right of use assets and lease liability	June 30, 2019 Right of use assets $ 398,698 June 30, 2019 Lease liability - right of use Current portion $ 167,437 Long term portion 272,413 $ 439,850
Lease liability maturities	Year ending December 31, Amount 2019 (remainder) $ 94,213 2020 191,713 2021 197,462 Total lease payments 483,388 Less: Present value adjustment (43,538 ) Lease liability - right of use $ 439,850
Future minimum lease payments	Year ending December 31, Amount 2019 (remainder) $ 94,213 2020 191,713 2021 197,462 Total $ 483,388

Note 12 - Revenue (Tables)

Note 12 - Revenue (Tables)	6 Months Ended
	Jun. 30, 2019
Revenue from Contract with Customer [Abstract]
Disaggregation of revenue	Three months ended March 31, 2019 Three months ended March 31, 2018 United States International Total United States International Total Product $ 120,488 $ 100,179 $ 220,667 $ 18,893 $ 224,572 $ 243,465 License fees 6,250 60,558 66,808 6,250 197,507 203,757 Other Revenue - 29,501 29,501 - 5,988 5,988 $ 126,738 $ 190,238 $ 316,976 $ 25,143 $ 428,067 $ 453,210 Six months ended June 30, 2019 Six months ended June 30, 2018 United States International Total United States International Total Product $ 138,167 $ 147,065 $ 285,232 $ 135,340 $ 346,693 $ 482,033 License fees 12,500 160,558 173,058 12,500 275,373 287,873 Other Revenue - 36,649 36,649 - 27,576 27,576 $ 150,667 $ 344,272 $ 494,939 $ 147,840 $ 649,642 $ 797,482

Note 15 - Earnings (Loss) Per_2

Note 15 - Earnings (Loss) Per Share (Tables)	6 Months Ended
	Jun. 30, 2019
LOSS PER SHARE:
Antidilutive shares	June 30, June 30, 2019 2018 Options 32,183,385 23,723,385 Warrants 39,568,407 108,355,714 Shares issuable 28,789,228 - Convertible promissory notes 26,004,347 - 126,545,367 132,079,099

Note 2 - Going Concern (Details

Note 2 - Going Concern (Details Narrative) - USD ($)	3 Months Ended				6 Months Ended
	Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2018	Mar. 31, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018	Dec. 31, 2017
Note 2 - Going Concern
Accumulated deficit	$ (120,254,865)				$ (120,254,865)		$ (116,602,778)
Cash and cash equivalents	154,446		$ 670,714		154,446	$ 670,714	$ 364,549	$ 730,184
Net cash used in operating activities					(3,402,634)	(1,598,202)
Net loss	$ (2,734,431)	$ (2,197,317)	$ (2,888,259)	$ (5,856,655)	$ (4,931,748)	$ (8,744,914)

Note 4 - Accrued Expenses (Deta

Note 4 - Accrued Expenses (Details) - USD ($)	Jun. 30, 2019	Dec. 31, 2018
Payables and Accruals [Abstract]
Accrued board of directors' fees	$ 300,000	$ 200,000
Accrued executive severance	145,000	136,000
Accrued outside services	124,078	115,118
Accrued inventory	116,502	0
Accrued travel	60,000	58,993
Accrued legal fees	35,000	0
Accrued clinical study expenses	13,650	13,650
Accrued related party advances	0	101,137
Deferred rent	0	44,623
Accrued computer equipment	0	8,752
Accrued other	1,228	11,007
Total accrued expenses	$ 795,458	$ 689,280

Note 5 - Contract Liabilities_2

Note 5 - Contract Liabilities (Details) - USD ($)	Jun. 30, 2019	Dec. 31, 2018
Total contract liabilities	$ 182,175	$ 178,533
Non-current contract liabilities	(67,361)	(46,736)
Current contract liabilities	114,814	131,797
Deposit on product
Total contract liabilities	62,946	92,950
Service agreement
Total contract liabilities	115,538	57,365
Other
Total contract liabilities	$ 3,691	$ 28,218

Note 8 - Notes Payable, Relat_2

Note 8 - Notes Payable, Related Parties (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018
Notes Payable [Abstract]
Notes payable principal	$ 5,372,743		$ 5,372,743		$ 5,372,743
Interest payable, current	1,504,453		1,504,453		$ 1,171,782
Interest expense, related party	$ 112,984	$ 194,246	$ 332,671	$ 383,457

Note 10 - Warrants (Details)

Note 10 - Warrants (Details)	6 Months Ended
	Jun. 30, 2019shares
Warrants outstanding, beginning	103,994,927
Warrants issued	365,000
Warrants exercised	(64,791,520)
Warrants expired	0
Warrants outstanding, ending	39,568,407
Class K Warrants
Warrants outstanding, beginning	7,200,000
Warrants issued	0
Warrants exercised	0
Warrants expired	0
Warrants outstanding, ending	7,200,000
Class L Warrants
Warrants outstanding, beginning	57,258,339
Warrants issued	0
Warrants exercised	(57,258,339)
Warrants expired	0
Warrants outstanding, ending	0
Class N Warrants
Warrants outstanding, beginning	30,451,815
Warrants issued	0
Warrants exercised	(6,237,499)
Warrants expired	0
Warrants outstanding, ending	24,214,316
Class O Warrants
Warrants outstanding, beginning	7,929,091
Warrants issued	0
Warrants exercised	(140,000)
Warrants expired	0
Warrants outstanding, ending	7,789,091
Class P Warrants
Warrants outstanding, beginning	0
Warrants issued	365,000
Warrants exercised	0
Warrants expired	0
Warrants outstanding, ending	365,000
Series A Warrants
Warrants outstanding, beginning	1,155,682
Warrants issued	0
Warrants exercised	(1,155,682)
Warrants expired	0
Warrants outstanding, ending	0

Note 10 - Warrants (Details 1)

Note 10 - Warrants (Details 1)	6 Months Ended
	Jun. 30, 2019$ / shares
Class K Warrants
Warrant exercise price/share	$ 0.08
Warrant expiration date	june 2025
Class K Warrants
Warrant exercise price/share	$ 0.11
Warrant expiration date	August 2027
Class N Warrants
Warrant exercise price/share	$ 0.11
Warrant expiration date	September 2019
Class O Warrants
Warrant exercise price/share	$ 0.11
Warrant expiration date	December 2019
Class P Warrants
Warrant exercise price/share	$ .20
Warrant expiration date	June 2024

Note 10 - Warrants (Details 2)

Note 10 - Warrants (Details 2)	6 Months Ended
	Jun. 30, 2019USD ($)
Warrant liability, beginning	$ 1,769,669
Change in fair value	(32,359)
Expired	(195,310)
Reclassification due to adoption of ASU 2017-11 (see Note 3)	(1,542,000)
Warrant liability, ending	0
Class K Warrants
Warrant liability, beginning	1,542,000
Change in fair value	0
Expired	0
Reclassification due to adoption of ASU 2017-11 (see Note 3)	(1,542,000)
Warrant liability, ending	0
Series A Warrants
Warrant liability, beginning	227,669
Change in fair value	(32,359)
Expired	(195,310)
Reclassification due to adoption of ASU 2017-11 (see Note 3)	0
Warrant liability, ending	$ 0

Note 11 - Commitments and Con_3

Note 11 - Commitments and Contingencies (Details) - USD ($)	Jun. 30, 2019	Dec. 31, 2018
Commitments and Contingencies Disclosure [Abstract]
Right of use assets	$ 398,698	$ 0
Lease liability - right of use, current	167,437	0
Lease liability - right of use, noncurrent	272,413	$ 0
Lease liability - right of use	$ 439,850

Note 11 - Commitments and Con_4

Note 11 - Commitments and Contingencies (Details 1)	Jun. 30, 2019USD ($)
Commitments and Contingencies Disclosure [Abstract]
2019 (remainder)	$ 94,213
2020	191,713
2021	197,462
Total payments	483,388
Less: imputed interest	(43,538)
Total operating lease liability	$ 439,850

Note 11 - Commitments and Con_5

Note 11 - Commitments and Contingencies (Details 2)	Jun. 30, 2019USD ($)
Commitments and Contingencies Disclosure [Abstract]
2019 (remainder)	$ 94,213
2020	191,713
2021	197,462
Total	$ 483,388

Note 11 - Commitments and Con_6

Note 11 - Commitments and Contingencies (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Commitments and Contingencies Disclosure [Abstract]
Rent expense	$ 54,698	$ 36,138	$ 107,536	$ 72,020

Note 12 - Revenue (Details)

Note 12 - Revenue (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Revenues	$ 316,976	$ 453,210	$ 494,939	$ 797,482
Product
Revenues	220,667	243,465	285,232	482,033
License fees
Revenues	66,808	203,757	173,058	287,873
Other
Revenues	29,501	5,988	36,649	27,576
United States
Revenues	126,738	25,143	150,667	147,840
United States | Product
Revenues	120,488	18,893	138,167	135,340
United States | License fees
Revenues	6,250	6,250	12,500	12,500
United States | Other
Revenues	0	0	0	0
International
Revenues	190,238	428,067	344,272	649,642
International | Product
Revenues	100,179	224,572	147,065	346,693
International | License fees
Revenues	60,558	197,507	160,558	275,373
International | Other
Revenues	$ 29,501	$ 5,988	$ 36,649	$ 27,576

Note 14 - Stock-based Compens_2

Note 14 - Stock-based Compensation (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018
Stock-based compensation - options and warrants	$ 31,758	$ 836,796	$ 31,758	$ 836,796
Stock Incentive Plan
Exercise prices for options, lower range limit			$ .02		$ 0.02
Exercise prices for options, upper range limit			$ 2		$ 2
Aggregate intrinsic value for vested and exercisable options	$ 664,516		$ 664,516		$ 2,085,866
Weighted average remaining contractual term for outstanding exercisable stock options			6 years 11 months 1 day		7 years 4 months 24 days

Note 15 - Earnings (Loss) Per_3

Note 15 - Earnings (Loss) Per Share (Details) - shares	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Anti-dilutive securities	126,545,367	132,079,099
Options
Anti-dilutive securities	32,183,385	23,723,385
Warrants
Anti-dilutive securities	39,568,407	108,355,714
Shares issuable
Anti-dilutive securities	28,789,228	0
Convertible Promissory Notes
Anti-dilutive securities	26,004,347	0